ImmunityBio, Inc. Annual Share-based Payment Arrangement, Expense in USD from 2013 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
ImmunityBio, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2013 to 2023.
  • ImmunityBio, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $7.49M, a 48.2% decline year-over-year.
  • ImmunityBio, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $38.2M, a 16.6% decline year-over-year.
  • ImmunityBio, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $49.2M, a 22.4% increase from 2022.
  • ImmunityBio, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $40.2M, a 29.7% decline from 2021.
  • ImmunityBio, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $57.2M, a 2515% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $49.2M +$8.98M +22.4% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-19
2022 $40.2M -$17M -29.7% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-19
2021 $57.2M +$55M +2515% Jan 1, 2021 Dec 31, 2021 10-K 2024-03-19
2020 $2.19M -$1.23M -36.1% Jan 1, 2020 Dec 31, 2020 10-K 2023-03-01
2019 $3.42M -$20M -85.4% Jan 1, 2019 Dec 31, 2019 10-K 2022-03-01
2018 $23.4M -$13.6M -36.8% Jan 1, 2018 Dec 31, 2018 10-K 2021-03-04
2017 $37M -$36.9M -49.9% Jan 1, 2017 Dec 31, 2017 10-K 2020-03-25
2016 $73.9M -$137M -65% Jan 1, 2016 Dec 31, 2016 10-K 2019-03-13
2015 $211M +$210M +26671% Jan 1, 2015 Dec 31, 2015 10-K 2018-03-12
2014 $789K -$95K -10.7% Jan 1, 2014 Dec 31, 2014 10-K 2017-03-15
2013 $884K Jan 1, 2013 Dec 31, 2013 10-K 2016-03-30
* An asterisk sign (*) next to the value indicates that the value is likely invalid.